# A Study to Evaluate the Efficacy and Safety of KarXT + KarX-EC for Cognitive Impairment in Alzheimer's Disease

> **NCT06976216** · PHASE3 · RECRUITING · sponsor: **Bristol-Myers Squibb** · enrollment: 586 (estimated)

## Conditions studied

- Alzheimer's Disease

## Interventions

- **DRUG:** KarXT
- **DRUG:** KarX-EC
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT06976216
- **Lead sponsor:** Bristol-Myers Squibb
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-07-14
- **Primary completion:** 2028-09-11
- **Final completion:** 2029-02-23
- **Target enrollment:** 586 (ESTIMATED)
- **Last updated:** 2026-05-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06976216

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06976216, "A Study to Evaluate the Efficacy and Safety of KarXT + KarX-EC for Cognitive Impairment in Alzheimer's Disease". Retrieved via AI Analytics 2026-05-21 from https://api.ai-analytics.org/clinical/NCT06976216. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*